Approaching the optimal transurethral resection of a bladder tumor
- PMID: 26328154
- PMCID: PMC4548374
- DOI: 10.5152/tud.2014.94715
Approaching the optimal transurethral resection of a bladder tumor
Abstract
A complete transurethral resection of a bladder tumor (TURBT) is essential for adequately diagnosing, staging, and treating bladder cancer. A TURBT is deceptively difficult and is a highly underappreciated procedure. An incomplete resection is the major reason for the high incidence of recurrence following initial transurethral resection and thus to the suboptimal care of our patients. Our objective was to review the preoperative, intraoperative, and postoperative considerations for performing an optimal TURBT. The European Association of Urology, Society of International Urology, and The American Urological Association guidelines emphasize a complete resection of all visible tumor during a TURBT. This review will emphasize the various techniques and treatments, including photodynamic cystoscopy, intravesical chemotherapy, and a perioperative checklist, that can be used to help to enable a complete resection and reduce the recurrence rate. A Medline/PubMed search was completed for original and review articles related to transurethral resection and the treatment of non-muscle-invasive bladder cancer. The major findings were analyzed and are presented from large prospective, retrospective, and review studies.
Keywords: Bladder cancer; checklist; fluorescence cystoscopy; narrow band imaging; transurethral resection.
Similar articles
-
Transurethral resection of bladder tumour (TURBT).Transl Androl Urol. 2020 Dec;9(6):3056-3072. doi: 10.21037/tau.2019.09.38. Transl Androl Urol. 2020. PMID: 33457279 Free PMC article. Review.
-
Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study).Trials. 2021 Feb 12;22(1):136. doi: 10.1186/s13063-021-05094-y. Trials. 2021. PMID: 33579327 Free PMC article.
-
Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial.JMIR Res Protoc. 2023 Jun 15;12:e42254. doi: 10.2196/42254. JMIR Res Protoc. 2023. PMID: 37318875 Free PMC article.
-
Initial experience with surrounding en bloc transurethral resection of bladder tumor and simultaneous intravesical treating for non-muscle invasive bladder cancer.BMC Urol. 2022 Nov 23;22(1):189. doi: 10.1186/s12894-022-01140-2. BMC Urol. 2022. PMID: 36419012 Free PMC article.
-
Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours.Eur Urol Oncol. 2021 Feb;4(1):12-19. doi: 10.1016/j.euo.2020.06.010. Epub 2020 Jul 16. Eur Urol Oncol. 2021. PMID: 32684515 Review.
Cited by
-
Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.Cancers (Basel). 2023 Jul 24;15(14):3746. doi: 10.3390/cancers15143746. Cancers (Basel). 2023. PMID: 37509407 Free PMC article.
-
Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.World J Urol. 2022 May;40(5):1111-1124. doi: 10.1007/s00345-021-03908-x. Epub 2022 Jan 27. World J Urol. 2022. PMID: 35083522 Review.
-
Transurethral resection of bladder tumour (TURBT).Transl Androl Urol. 2020 Dec;9(6):3056-3072. doi: 10.21037/tau.2019.09.38. Transl Androl Urol. 2020. PMID: 33457279 Free PMC article. Review.
-
Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System.Front Oncol. 2019 Dec 11;9:1402. doi: 10.3389/fonc.2019.01402. eCollection 2019. Front Oncol. 2019. PMID: 31921659 Free PMC article.
References
-
- Lee F, Patel HR, Emberton M. The ‘top 10’ urological procedures: a study of hospital episodes statistics 1998–99. BJU Int. 2002;90:1–6. - PubMed
-
- Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–42. - PubMed
-
- American Urological Association: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. Linthicum, Maryland: American Urological Association; 2007. Available at www.auanet.org. - PubMed
-
- Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. [EAU guidelines on non-muscle-carcinoma of the bladder] Actas Urol Esp. 2009;33:361–71. - PubMed
-
- Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:36–44. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources